Abstract Title:

The natural products parthenolide and andrographolide exhibit anti-cancer stem cell activity in multiple myeloma.

Abstract Source:

Leuk Lymphoma. 2011 Jun ;52(6):1085-97. Epub 2011 Mar 21. PMID: 21417826

Abstract Author(s):

Ellen J Gunn, John T Williams, Daniel T Huynh, Michael J Iannotti, Changho Han, Francis J Barrios, Stephen Kendall, Carlotta A Glackin, David A Colby, Julia Kirshner

Article Affiliation:

Department of Biological Sciences, Purdue University, West Lafayette, IN 47907, USA.

Abstract:

Multiple myeloma (MM) is an incurable plasma cell malignancy where nearly all patients succumb to a relapse. The current preclinical models of MM target the plasma cells, constituting the bulk of the tumor, leaving the cancer stem cells to trigger a relapse. Utilizing a three-dimensional tissue culture system where cells were grown in extracellular matrix designed to reconstruct human bone marrow, we tested the anti-multiple myeloma cancer stem cell (MM-CSC) potential of two natural product inhibitors of nuclear factorκB (NFκB). Here we show that parthenolide and andrographolide are potent anti-MM-CSC agents. Both natural products demonstrated preferential toxicity toward MM-CSCs over non-tumorigenic MM cells. Addition of the bone marrow stromal compartment abrogated andrographolide activity while having no effect on parthenolide cytoxicity. This is the first report of a natural product with anti-CSC activity in myeloma, suggesting that it has the potential to improve the survival of patients with MM by eliminating the relapse-causing MM-CSCs.

Print Options


This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.